IL219248A - Derivatives 2 - [(4-amino-3-hydroxyphenyl-h1- pyrazolo [4,3- c] pyrimidin-1-yl) methyl] -5- (propinyl) quinazoline-4- (h3) - van, intermediates in process For their preparation and pharmaceutical preparations containing them - Google Patents

Derivatives 2 - [(4-amino-3-hydroxyphenyl-h1- pyrazolo [4,3- c] pyrimidin-1-yl) methyl] -5- (propinyl) quinazoline-4- (h3) - van, intermediates in process For their preparation and pharmaceutical preparations containing them

Info

Publication number
IL219248A
IL219248A IL219248A IL21924812A IL219248A IL 219248 A IL219248 A IL 219248A IL 219248 A IL219248 A IL 219248A IL 21924812 A IL21924812 A IL 21924812A IL 219248 A IL219248 A IL 219248A
Authority
IL
Israel
Prior art keywords
derivatives
quinazolin
pyrazolo
pyrimidin
propynyl
Prior art date
Application number
IL219248A
Other languages
English (en)
Hebrew (he)
Other versions
IL219248A0 (en
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL219248(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of IL219248A0 publication Critical patent/IL219248A0/en
Publication of IL219248A publication Critical patent/IL219248A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL219248A 2009-10-19 2012-04-18 Derivatives 2 - [(4-amino-3-hydroxyphenyl-h1- pyrazolo [4,3- c] pyrimidin-1-yl) methyl] -5- (propinyl) quinazoline-4- (h3) - van, intermediates in process For their preparation and pharmaceutical preparations containing them IL219248A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918249.4A GB0918249D0 (en) 2009-10-19 2009-10-19 Compounds
PCT/EP2010/065746 WO2011048111A1 (en) 2009-10-19 2010-10-19 Compounds

Publications (2)

Publication Number Publication Date
IL219248A0 IL219248A0 (en) 2012-06-28
IL219248A true IL219248A (en) 2015-02-26

Family

ID=41462531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219248A IL219248A (en) 2009-10-19 2012-04-18 Derivatives 2 - [(4-amino-3-hydroxyphenyl-h1- pyrazolo [4,3- c] pyrimidin-1-yl) methyl] -5- (propinyl) quinazoline-4- (h3) - van, intermediates in process For their preparation and pharmaceutical preparations containing them

Country Status (35)

Country Link
US (4) US8741909B2 (enExample)
EP (1) EP2491037B1 (enExample)
JP (1) JP5889792B2 (enExample)
KR (1) KR101770616B1 (enExample)
CN (1) CN102712645B (enExample)
AR (1) AR078674A1 (enExample)
AU (1) AU2010309832B2 (enExample)
BR (1) BR112012009214A2 (enExample)
CA (1) CA2777902C (enExample)
CL (1) CL2012000981A1 (enExample)
CR (1) CR20120264A (enExample)
CY (1) CY1116057T1 (enExample)
DK (1) DK2491037T3 (enExample)
EA (1) EA020330B3 (enExample)
EC (1) ECSP12011805A (enExample)
ES (1) ES2477270T3 (enExample)
GB (1) GB0918249D0 (enExample)
HR (1) HRP20140599T1 (enExample)
IL (1) IL219248A (enExample)
ME (1) ME02064B (enExample)
MX (1) MX2012004525A (enExample)
MY (1) MY164731A (enExample)
NI (2) NI201200061A (enExample)
NZ (2) NZ599162A (enExample)
PE (1) PE20121390A1 (enExample)
PH (1) PH12012500620A1 (enExample)
PL (1) PL2491037T3 (enExample)
PT (1) PT2491037E (enExample)
RS (1) RS53385B (enExample)
SI (1) SI2491037T1 (enExample)
SM (1) SMT201400086B (enExample)
TW (1) TWI478923B (enExample)
UA (1) UA108743C2 (enExample)
WO (1) WO2011048111A1 (enExample)
ZA (1) ZA201203662B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
TWI617561B (zh) 2012-03-13 2018-03-11 瑞斯比維特有限公司 呈晶體型式之新穎化合物，包含其之醫藥組成物，製備該化合物之方法及包括該組成物之吸入裝置
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
JO3279B1 (ar) * 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
CN105431157A (zh) 2013-06-14 2016-03-23 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PH12016500582B1 (en) 2013-10-04 2023-06-30 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
PE20170640A1 (es) 2014-07-04 2017-05-26 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2019143874A1 (en) * 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN108516976B (zh) * 2018-04-27 2020-07-03 四川大学华西医院 一种7-脱氮嘌呤衍生物及其四元环超分子结构
EP3852763A1 (en) * 2018-09-18 2021-07-28 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CZ303154B6 (cs) 1998-11-13 2012-05-09 Jagotec Ag Suchá prášková formulace k inhalaci obsahující stearát horecnatý
DE60004781T2 (de) 1999-01-11 2004-07-08 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2567260T3 (es) 2000-04-25 2016-04-21 Icos Corporation Inhibidores de la fosfatidilinositol 3-quinasa delta humana
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1578898A2 (en) 2001-07-13 2005-09-28 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
WO2005112935A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2566609C (en) * 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
BRPI0515164A (pt) 2004-09-13 2008-07-08 Ono Pharmaceutical Co derivado heterocìclico nitrogenado e medicamento contendo o mesmo como um ingrediente ativo
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
DK2004654T3 (da) * 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
EA200802348A1 (ru) 2006-05-24 2009-08-28 Байер Шеринг Фарма Акциенгезельшафт ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
EA200901488A1 (ru) * 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101965335B (zh) 2008-01-04 2015-01-14 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2346508B1 (en) * 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
IN2012DN01254A (enExample) 2009-08-05 2015-05-15 Versitech Ltd
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
BR112013007022B1 (pt) 2010-09-30 2019-10-15 Chiesi Farmaceutici S.P.A Uso de estearato de magnésio
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
TWI617561B (zh) 2012-03-13 2018-03-11 瑞斯比維特有限公司 呈晶體型式之新穎化合物，包含其之醫藥組成物，製備該化合物之方法及包括該組成物之吸入裝置

Also Published As

Publication number Publication date
CA2777902A1 (en) 2011-04-28
US8741909B2 (en) 2014-06-03
WO2011048111A1 (en) 2011-04-28
GB0918249D0 (en) 2009-12-02
UA108743C2 (uk) 2015-06-10
SMT201400086B (it) 2014-09-08
CN102712645B (zh) 2015-10-21
CN102712645A (zh) 2012-10-03
HRP20140599T1 (hr) 2014-09-12
ECSP12011805A (es) 2012-06-29
AR078674A1 (es) 2011-11-23
DK2491037T3 (da) 2014-07-21
NZ599162A (en) 2013-08-30
BR112012009214A2 (pt) 2016-08-16
CY1116057T1 (el) 2017-02-08
EP2491037A1 (en) 2012-08-29
NI201300035A (es) 2013-06-04
SI2491037T1 (sl) 2014-08-29
EA201270575A1 (ru) 2012-09-28
KR101770616B1 (ko) 2017-08-23
EP2491037B1 (en) 2014-04-30
HK1173728A1 (en) 2013-05-24
AU2010309832B2 (en) 2014-01-30
EA020330B1 (ru) 2014-10-30
PH12012500620A1 (en) 2015-03-20
AU2010309832A1 (en) 2012-04-19
NZ609147A (en) 2014-03-28
JP5889792B2 (ja) 2016-03-22
EA020330B3 (ru) 2015-07-30
US9321773B2 (en) 2016-04-26
IL219248A0 (en) 2012-06-28
PL2491037T3 (pl) 2014-09-30
US20160264583A1 (en) 2016-09-15
ES2477270T3 (es) 2014-07-16
RS53385B (sr) 2014-10-31
PE20121390A1 (es) 2012-10-15
ZA201203662B (en) 2013-10-30
MX2012004525A (es) 2012-05-29
US20180118754A1 (en) 2018-05-03
TW201124418A (en) 2011-07-16
CL2012000981A1 (es) 2012-08-31
MY164731A (en) 2018-01-30
US20140249164A1 (en) 2014-09-04
JP2013508334A (ja) 2013-03-07
CA2777902C (en) 2018-03-06
NI201200061A (es) 2013-05-15
US9834560B2 (en) 2017-12-05
US20120208799A1 (en) 2012-08-16
PT2491037E (pt) 2014-07-11
TWI478923B (zh) 2015-04-01
CR20120264A (es) 2013-01-25
ME02064B (me) 2015-05-20
KR20120114225A (ko) 2012-10-16

Similar Documents

Publication Publication Date Title
IL219248A (en) Derivatives 2 - [(4-amino-3-hydroxyphenyl-h1- pyrazolo [4,3- c] pyrimidin-1-yl) methyl] -5- (propinyl) quinazoline-4- (h3) - van, intermediates in process For their preparation and pharmaceutical preparations containing them
IL212339A (en) Pyrolobenzodiazepine derivatives and processes for their preparation
IL194835A (en) History of cyclohexylpyrazole-lactam, an intermediate substance for their use in the preparation of drugs
IL215911A (en) 7-aryl-1,2,4-triazolo [3,4- a] derivatives, pharmaceutical preparations containing them and methods of preparation and uses thereof
SI2044076T1 (sl) Postopek za pripravo azenapina in vmesni produkti, uporabljeni v tem postopku
IL192009A0 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
IL207038A (en) History of Diazaspiro [5.5] Undecan, Pharmaceuticals Containing them, and their use in the preparation of drugs for the treatment or reduction of the risk of disease or inflammatory condition
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
IL203206A (en) 2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing
IL223253B (en) History of 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine and their use in the preparation of drugs against pneumovirina
IL196601A (en) 2-morpholine-4-yl (pyrolidino / piperidino) pyrimidine, pharmaceuticals containing them and intermediates in the process of preparation
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL203292A (en) History of n-indazolil affluent, process for preparation, intermediates obtained in this process and pharmacological preparations containing the history
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
IL208355A (en) Annotations 7,3-Dihydroporin-6,2-Discussion, Processes for their Preparation, Pharmaceutical Preparations Containing them and their Use in Medication Preparation
IL215059A (en) Liposome preparation that includes an arboline and a process for its preparation
IL218490A (en) Oxazolopyrimidinones dihydro hydroxybencyalkyloxymethyl are converted, preparations containing them and their use in the preparation of pharmaceutical preparations
EP2456471A4 (en) IRON-BASED PREPARATION FOR USE IN PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREOF
IL215158A (en) History of imidazo [1,2– b] [4,3,1] thadiazole preserved in positions 2 and 5, a process for preparing them and their pharmaceutical preparations
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
IL210708A0 (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
IL210074A0 (en) Compositions with and process for methylmorpholin-substituted pyrido[2,3-d]pyrimidines
SI2448940T1 (sl) Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees